-
Activation of circulating TFH17 cells associated with activated naive and double negative 2 B cell expansion, and disease activity in systemic lupus erythematosus patients Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-09-11 Tipanan Khunsri, Pongsakorn Thawornpan, Pachara Tianpothong, Thanitta Suangtamai, Pintip Ngamjanyaporn, Chaniya Leepiyasakulchai, Kittikorn Wangriatisak, Prapaporn Pisitkun, Patchanee Chootong
Systemic lupus erythematosus (SLE) is the quintessential autoimmune disease, as it is characterized by hyperactivity of CD4+ T cells and subsequently drives lupus pathology. Follicular helper T (TFH) cells play an important role in B cell maturation and antibody production. However, which specific subset of cTFH cells drives B cell function and contributes to the development of anti-dsDNA antibodies
-
Association of anti-HMGCR antibodies of the IgM isotype with refractory immune-mediated necrotizing myopathy Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-09-11 Hongxia Yang, Chao Sun, Lifang Ye, Yuetong Xu, Sang Lin, Qinglin Peng, Guochun Wang, Xin Lu
Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) autoantibodies are one of the myositis-specific antibodies which is associated with immune-mediated necrotizing myopathy (IMNM). However, the relationship between anti-HMGCR isotypes and prognosis has not yet been fully investigated. This study was conducted to gain insight into the association between anti-HMGCR isotypes and clinical, and
-
A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48) Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-09-07 Xiaomei Leng, Piotr Leszczyński, Slawomir Jeka, Shengyun Liu, Huaxiang Liu, Malgorzata Miakisz, Jieruo Gu, Lali Kilasonia, Mykola Stanislavchuk, Xiaolei Yang, Yinbo Zhou, Qingfeng Dong, Marian Mitroiu, Janet Addison, Mourad F. Rezk, Xiaofeng Zeng
Equivalent efficacy and comparable pharmacokinetic, immunogenicity, and safety profiles of the biosimilar BAT1806/BIIB800 and reference tocilizumab (TCZ) in participants with moderate-to-severe rheumatoid arthritis (RA) have been reported up to week 24 (treatment period [TP] 1) of the phase 3 study. Here we present results for TP2 (study weeks 24–48). In this phase 3, multicenter, multiregional, double-blind
-
Factors related to elevated serum immunoglobulin G4 (IgG4) levels in a Japanese general population Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-09-06 Shunsuke Tsuge, Hiroshi Fujii, Mami Tamai, Hiromasa Tsujiguchi, Misaki Yoshida, Nobuhiro Suzuki, Yoshinori Takahashi, Akari Takeji, Shigeto Horita, Yuhei Fujisawa, Takahiro Matsunaga, Takeshi Zoshima, Ryo Nishioka, Hiromi Nuka, Satoshi Hara, Yukiko Tani, Yasunori Suzuki, Kiyoaki Ito, Kazunori Yamada, Satoshi Nakazaki, Akinori Hara, Atsushi Kawakami, Hiroyuki Nakamura, Ichiro Mizushima, Yasunori Iwata
Elevated serum immunoglobulin G4 (IgG4) concentrations are one of the characteristic findings in IgG4-related disease (IgG4-RD). This study investigated the frequency of elevated serum IgG4 levels and associated factors in a general Japanese population. Serum IgG4 concentrations were measured in 1,201 residents of Ishikawa prefecture who underwent general medical examinations. Factors associated with
-
A Bayesian model to analyse the association of comorbidities with biosimilar treatment retention in a non-medical switch scenario in patients with inflammatory rheumatic musculoskeletal diseases Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-09-04 Imke Redeker, Stefan Moustakis, Styliani Tsiami, Xenofon Baraliakos, David Kiefer, Ioana Andreica, Björn Buehring, Jürgen Braun, Uta Kiltz
To analyse clinical outcomes of a non-medical switch from originator adalimumab (ADA) to its ABP501 biosimilar (ABP) over 6 months in patients with inflammatory rheumatic musculoskeletal diseases (RMD) in relation to comorbidity as a risk factor for therapy discontinuation. RMD patients switching from originator ADA to ABP were identified from a large routine database from October 2018 onwards. Documented
-
Correction: S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-08-31 Hermine I Brunner, Grant S Schulert, Alyssa Sproles, Sherry Thornton, Gabriel Vega Cornejo, Jordi Antón, Ruben Cuttica, Michael Henrickson, Ivan Foeldvari, Daniel J Kingsbury, Margarita Askelson, Jinqi Liu, Sumanta Mukherjee, Robert L Wong, Daniel J Lovell, Alberto Martini, Nicolino Ruperto, Alexei A Grom
Correction: Arthritis Res Ther 26, 125 (2024) https://doi.org/10.1186/s13075-024-03347-0 Following publication of the original article [1], the authors reported an error to Supplementary Material 2. Supplementary Material 2 was removed as the file was only for the reviewers’ reference and not meant to be published. The original article [1] has been updated. Brunner HI, Schulert GS, Sproles A, et al
-
Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-08-27 Merete Lund Hetland, Anja Strangfeld, Gianluca Bonfanti, Dimitrios Soudis, J. Jasper Deuring, Roger A. Edwards
Patients with rheumatoid arthritis (RA) have an increased risk of developing serious infections (SIs) vs. individuals without RA; efforts to predict SIs in this patient group are ongoing. We assessed the ability of different machine learning modeling approaches to predict SIs using baseline data from the tofacitinib RA clinical trials program. This analysis included data from 19 clinical trials (phase
-
Association of anti-Ro-52 antibodies with occurrence of interstitial lung disease in patients with idiopathic inflammatory myopathy Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-08-22 Chia-Tse Weng, Tang-Hsiu Huang, Chun-Hsin Wu, Yuan-Ting Sun
Anti-Ro-52 antibodies have been associated with interstitial lung disease (ILD) in various autoimmune diseases. However, their role in ILD among patients with idiopathic inflammatory myopathies (IIMs) is relatively underexplored. This study aimed to investigate the association between anti-Ro-52 antibodies and the occurrence of ILD in individuals with IIMs. This retrospective observational study included
-
Analysis of risk factors and development of a nomogram prediction model for renal tubular acidosis in primary Sjogren syndrome patients Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-08-22 Yanzhen Zeng, Runzhi Liu, Shuyi Li, Jingwen Wei, Fei Luo, Yongkang Chen, Dongmei Zhou
To investigate the risk factors of renal tubular acidosis (RTA) in patients with primary Sjögren’s syndrome (pSS) and create a personalized nomogram for predicting pSS-RTA patients. Data from 99 pSS patients who underwent inpatient treatment at our hospital from January 2012 to January 2024 were retrospectively collected and analyzed. Bootstrap resampling technique, single-factor, and multi-factor
-
Inclusion of fibrinoid necrosis increases the accuracy of synovial tissue assessment in predicting response to methotrexate: analysis of the UCLouvain Brussels ERA Cohort Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-08-19 Francesco Natalucci, Clément Triaille, Cécile Van Mullem, Tatiana Sokolova, Emilie Sapart, Laurent Meric de Bellefon, Adrien Nzeusseu, Christine Galant, Bernard Lauwerys, Patrick Durez
Rheumatoid Arthritis (RA) often exhibits suboptimal treatment response despite early diagnosis and treatment. This study aimed to analyze Early Rheumatoid Arthritis (ERA) synovial biopsies through histology and immunohistochemistry (IHC) to identify predictive factors for treatment response to Methotrexate (MTX). 140 ERA patients from the UCLouvain Arthritis Cohort underwent synovial biopsy and were
-
Retraction Note: Fibroblast growth factor receptor 1 is principally responsible for fibroblast growth factor 2-induced catabolic activities in human articular chondrocytes Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-08-07 Dongyao Yan, Di Chen, Simon M Cool, Andre J van Wijnen, Katalin Mikecz, Gillian Murphy, Hee-Jeong Im
Retraction Note: Arthritis Res Ther 13, R130 (2011) https://doi.org/10.1186/ar3441 The Editors-in-Chief have retracted this article because an investigation jointly conducted by Rush University and the Jesse Brown Veterans Affairs Medical Center (JBVAMC) has determined that Fig. 5B contains fabricated and/or falsified data. Gillian Murphy agrees with this retraction. Simon M. Cool, Andre J. van Wijnen
-
The mode of action of IL-23 in experimental inflammatory arthritic pain and disease Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-08-06 Kevin M.-C. Lee, Tanya Lupancu, Leon Chang, Carl L. Manthey, Martha Zeeman, Anne M. Fourie, John A. Hamilton
We have previously reported using gene-deficient mice that the interleukin (IL)-23p19 subunit is required for the development of innate immune-driven arthritic pain and disease. We aimed to explore here, using a number of in vivo approaches, how the IL-23p19 subunit can mechanistically control arthritic pain and disease in a T- and B- lymphocyte-independent manner. We used the zymosan-induced arthritis
-
Significant overlap of inflammatory and degenerative features on imaging among patients with degenerative disc disease, diffuse idiopathic skeletal hyperostosis and axial spondyloarthritis: a real-life cohort study Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-08-03 Nelly Ziade, Melanie Udod, Nikolaos Kougkas, Styliani Tsiami, Xenofon Baraliakos
Differentiating between degenerative disc disease (DDD), diffuse idiopathic skeletal hyperostosis (DISH), and axial spondyloarthritis (axSpA) represents a diagnostic challenge in patients with low back pain (LBP). We aimed to evaluate the distribution of inflammatory and degenerative imaging features in a real-life cohort of LBP patients referred to a tertiary university rheumatology center. In a retrospective
-
IL-40 is up-regulated in the synovial fluid and cartilage of osteoarthritis patients and contributes to the alteration of chondrocytes phenotype in vitro Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-30 L. Andrés Cerezo, A. Navrátilová, M. Kuklová, A. Prokopcová, J. Baloun, T. Kropáčková, D. Veigl, S. Popelka, P. Fulín, R. Ballay, K. Pavelka, J. Vencovský, L. Šenolt
IL-40 is a novel cytokine associated with autoimmune connective tissue disorders such as rheumatoid arthritis (RA) or Sjögren syndrome. We have previously shown an accumulation of IL-40 in the RA joint and its expression by immune cells and fibroblasts. Therefore, we aimed to assess the role of IL-40 in association with hyaline cartilage and chondrocyte activity. Immunohistochemistry was employed to
-
Infrapatellar fat pad size and subcutaneous fat in knee osteoarthritis radiographic progression: data from the osteoarthritis initiative Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-30 Kwanghoon Lee, Marina Banuls-Mirete, Alecio F. Lombardi, Alexander I.B. Posis, Eric Y. Chang, Nancy E. Lane, Monica Guma
Adipose tissue has been associated with knee osteoarthritis (KOA) pathogenesis, but the longitudinal changes in adipose tissue with KOA progression have not been carefully evaluated. This study aimed to determine if longitudinal changes of systemic and local adipose tissue is associated with radiographic progression of KOA. This case-control study used data from the Osteoarthritis Initiative (OAI)
-
Expression of CD163 and major histocompatibility complex class I as diagnostic markers for idiopathic inflammatory myopathies Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-30 Byeongzu Ghang, So Hye Nam, Wonho Choi, Hwa Jung Kim, Jungsun Lee, Doo-Ho Lim, Soo Min Ahn, Ji Seon Oh, Seokchan Hong, Yong-Gil Kim, Chang-Keun Lee, Jinseok Kim, Bin Yoo, Soo Jeong Nam
To develop an inflammation-related immunohistochemistry marker-based algorithm that confers higher diagnostic ability for idiopathic inflammatory myopathies (IIMs) than IIM-related histopathologic features. Muscle biopsy tissues from 129 IIM patients who met the 2017 EULAR/ACR criteria and 73 control tissues from patients with non-inflammatory myopathies or healthy muscle specimens were evaluated for
-
Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-29 Ronald van Vollenhoven, Vibeke Strand, Tsutomu Takeuchi, Nilmo Chávez, Pablo Mannucci Walter, Atul Singhal, Jerzy Swierkot, Nasser Khan, Xianwei Bu, Yihan Li, Sara K. Penn, Heidi S. Camp, Jacob Aelion
To evaluate the efficacy and safety of upadacitinib monotherapy versus methotrexate (MTX) monotherapy over 5 years among MTX-naïve patients with moderately to severely active rheumatoid arthritis (RA) in the long-term extension (LTE) of the phase 3 SELECT-EARLY trial. Patients were randomized to receive upadacitinib 15 mg or 30 mg or MTX. Patients who did not achieve CDAI remission and had < 20% improvement
-
Correlation of high-resolution computed tomography and immunological bronchoalveolar lavage in interstitial lung disease at the onset of inflammatory rheumatic diseases: implications for diagnosis and therapeutic strategies Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-29 Tobias Hoffmann, Ulf Teichgräber, Martin Förster, Peter Oelzner, Claus Kroegel, Diane Renz, Tobias Weise, Joachim Böttcher, P. Christian Schulze, Gunter Wolf, Marcus Franz, Alexander Pfeil
Inflammatory rheumatic diseases (IRD) are often associated with interstitial lung disease (ILD). The aim of the present study was to establish a correlation between the findings on HRCT and the immunological bronchoalveolar lavage (BAL). The study included 74 patients with newly diagnosed IRD and evidence of ILD on HRCT with the following pattern: ground-glass opacities (GGO), non-specific interstitial
-
Performance of standardized patient reported outcomes developed for spondyloarthritis in primary and concomitant forms of fibromyalgia Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-26 Styliani Tsiami, Piet Dukatz, Maria Gkelaki, Philipp Sewerin, Uta Kiltz, Xenofon Baraliakos
In spondyloarthritides (SpA) and fibromyalgia (FM), patients suffer from generalized pain. The impact of FM on PRO validated in SpA has not been systematically studied. Study the performance of PROs developed for SpA in patients with primary (p) FM without chronic inflammatory-rheumatic disease vs. SpA without and with concomitant (c) FM. Patients with pFM, axSpA or PsA and indication for treatment
-
Predictors of functional improvement and pain reduction in rheumatoid arthritis patients who achieved low disease activity with disease-modifying antirheumatic drugs: a retrospective study of the FIRST Registry Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-26 Sae Ochi, Koshiro Sonomoto, Shingo Nakayamada, Yoshiya Tanaka
Rheumatoid arthritis (RA) patients sometimes exhibit different levels of improvement in health assessment questionnaire-disability index (HAQ-DI) and subjective pain visual analogue score (VAS) even after achieving low disease activities (LDA). This study aimed to identify factors associated with improvement in HAQ-DI and pain VAS among those who achieved LDA. Data of the FIRST registry, a multi-institutional
-
Elevated neutrophil extracellular traps in systemic sclerosis-associated vasculopathy and suppression by a synthetic prostacyclin analog Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-25 Neda Kortam, Wenying Liang, Claire Shiple, Suiyuan Huang, Rosemary Gedert, James St. Clair, Cyrus Sarosh, Caroline Foster, Pei-Suen Tsou, John Varga, Jason S. Knight, Dinesh Khanna, Ramadan A. Ali
Neutrophils and neutrophil extracellular traps (NETs) contribute to the vascular complications of multiple diseases, but their role in systemic sclerosis (SSc) is understudied. We sought to test the hypothesis that NETs are implicated in SSc vasculopathy and that treatment with prostacyclin analogs may ameliorate SSc vasculopathy not only through vasodilation but also by inhibiting NET release. Blood
-
Prevalence and location of inflammatory and structural lesions in patients with rheumatoid arthritis and radiographic axial spondyloarthritis with chronic neck pain evaluated by magnetic resonance imaging Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-25 David Kiefer, Mina Soltani, Parham Damirchi, Uta Kiltz, Bjoern Buehring, Ioana Andreica, Philipp Sewerin, Xenofon Baraliakos
Define the prevalence and location of inflammatory and structural lesions on magnetic resonance imaging (MRI) in patients with rheumatoid arthritis (RA) and radiographic axial spondyloarthritis (r-axSpA) with neck pain as leading clinical symptom. Patients with diagnosis of RA and r-axSpA were consecutively included if they had chronic (> 3 months) neck pain. Clinical assessment, neck pain questionnaires
-
Risk factors of mortality in patients with rheumatoid arthritis-associated interstitial lung disease: a single-centre prospective cohort study Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-19 Yeo-Jin Song, Hyoungyoung Kim, Soo-Kyung Cho, Hye Won Kim, Chaewhi Lim, Eunwoo Nam, Chan-Bum Choi, Tae-Hwan Kim, Jae-Bum Jun, Sang-Cheol Bae, Dae Hyun Yoo, Su Jin Hong, Seung-Jin Yoo, Youkyung Lee, Yoon-Kyoung Sung
To determine the risk factors for mortality in Korean patients with rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) in comparison to patients with RA but without ILD (RA-nonILD). Data were extracted from a single-centre prospective cohort of RA patients with a chest computed tomography scan at an academic referral hospital in Korea. Patients with RA-ILD enroled between May 2017
-
Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-18 Panagiota Xanthouli, Paul Uesbeck, Hanns-Martin Lorenz, Norbert Blank, Christina A. Eichstaedt, Satenik Harutyunova, Benjamin Egenlauf, Jerry G. Coghlan, Christopher P. Denton, Ekkehard Grünig, Nicola Benjamin
In the EDITA trial, patients with systemic sclerosis (SSc) and mild pulmonary vascular disease (PVD) treated with ambrisentan had a significant decline of pulmonary vascular resistance (PVR) but not of mean pulmonary arterial pressure (mPAP) vs. placebo after six months. The EDITA-ON study aimed to assess long-term effects of open label therapy with ambrisentan vs. no pulmonary arterial hypertension
-
Stabilizing the integrity of intestinal barrier to control arthritis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-18 George D. Kalliolias, Athanasios G. Papavassiliou
With great interest, we have read the recent article “Expression of HIF1α in intestinal epithelium restricts arthritis inflammation by inhibiting RIPK3-induced cell death machinery” published by Lyu et al. in Annals of the Rheumatic Diseases. The authors pose that the expression of hypoxia-inducible factor 1 alpha in intestinal epithelial cells represents a crucial check point for the development of
-
JAK inhibitors attenuate hyperactivation of nonswitched memory B cells in rheumatoid arthritis patients in remission Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-17 Jing Luo, Jing Zhang, Bomiao Ju, Yanhua Wang, Nan Hu, Qian Li, Qianyun Xu, Dan Pu, Zhiming Hao, Yongwei Huo, Xiaohong Lv, Lan He
To investigate the distribution and activation of B-cell subpopulations in rheumatoid arthritis (RA) patients treated with Janus kinase inhibitors (JAKis) and to analyze their correlation with disease remission. Peripheral blood samples were collected from 23 adult healthy controls and 58 RA patients, 31 of whom were treated with JAKis and assessed during a 24-month follow-up. The number of peripheral
-
A novel method to monitor rheumatoid arthritis prevalence using hospital and medication databases Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-16 Louise Koller-Smith, Ahmed Mehdi, Lyn March, Leigh Tooth, Gita D. Mishra, Ranjeny Thomas
Most estimates of rheumatoid arthritis (RA) prevalence, including all official figures in Australia and many other countries, are based on self-report. Self-report has been shown to overestimate RA, but the ‘gold standard’ of reviewing individual medical records is costly, time-consuming and impractical for large-scale research and population monitoring. This study provides an algorithm to estimate
-
Clinical relevance of positively determined myositis antibodies in rheumatology: a retrospective monocentric analysis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-16 Falk Schumacher, Maximilian Zimmermann, Malte Kanbach, Wigbert Schulze, Maximilian Wollsching-Strobel, Doreen Kroppen, Sarah Bettina Stanzel, Daniel Majorski, Wolfram Windisch, Johannes Strunk, Melanie Berger
The increased availability of myositis autoantibodies represents new possibilities and challenges in clinical practice (Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76:1955–64
-
TGFβ signaling pathway is altered by HLA-B27 expression, resulting in pathogenic consequences relevant for spondyloarthritis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-15 Marc Lauraine, Maxence de Taffin de Tilques, Dganit Melamed-Kadosh, Bilade Cherqaoui, Vincent Rincheval, Erwan Prevost, Aurore Rincheval-Arnold, Eneida Cela, Arie Admon, Isabelle Guénal, Luiza M. Araujo, Maxime Breban
Association of HLA-B27 with spondyloarthritis (SpA) has been known for 50 years, but still remains unexplained. We recently showed that HLA-B27 expressed in wing imaginal disc from HLA-B27/human-β2 microglobulin (hβ2m) transgenic Drosophila deregulated bone morphogenetic protein (BMP) pathway by interacting physically with type I BMP receptor (BMPR1) Saxophone (Sax), leading to crossveinless phenotype
-
Serum GM-CSF level is a predictor of treatment response to tocilizumab in rheumatoid arthritis patients: a prospective observational cohort study Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-12 Jingbo Su, Wenlu Hu, Yanxia Ding, Panpan Zhang, Tianfang Li, Shengyun Liu, Lihua Xing
The aim of this prospective observational cohort study was to unveil the predictors of treatment response to tocilizumab (TCZ) therapy in rheumatoid arthritis (RA) patients, in terms of clinical characteristics and serum proinflammatory cytokines, especially to explore the predictive value of granulocyte macrophage-colony stimulating factor (GM-CSF). Active adult RA patients with inadequate response
-
The dual amylin and calcitonin receptor agonist KBP-336 elicits a unique combination of weight loss, antinociception and bone protection – a novel disease-modifying osteoarthritis drug Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-12 Khaled Elhady Mohamed, Anna Thorsø Larsen, Simone Melander, Frederik Andersen, Ellen Barendorff Kerrn, Morten Asser Karsdal, Kim Henriksen
Despite the extensive research to provide a disease-modifying osteoarthritis drug (DMOAD), there is still no approved DMOAD. Dual amylin and calcitonin receptor agonists (DACRA) can provide metabolic benefits along with antinociceptive and potential structural preserving effects. In these studies, we tested a DACRA named KBP-336 on a metabolic model of OA in meniscectomised (MNX) rats. We evaluated
-
Correction: Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-09 Javier Narvaez, Elena Canadillas, Ivan Castellvi, Juan Jose Alegre, Vanesa Vicens‑Zygmunt, Guadalupe Bermudo, Paola Vidal-Montal, Maria Molina Molina, Joan Miquel Nolla
Correction: Arthritis Res Ther 26, 122 (2024) https://doi.org/10.1186/s13075-024-03353-2 Following publication of the original article [1], the authors identified an error in the author name of Vanesa Vicens‑Zygmunt. The incorrect author name is: Vanesa Vincens‑Zygmunt. The correct author name is: Vanesa Vicens‑Zygmunt. The author group has been updated above and the original article [1] has been corrected
-
The Relationship between the complement system and subclinical carotid atherosclerosis in patients with rheumatoid arthritis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-08 Marta Hernández-Díaz, Dara Rodríguez-González, Elena Heras-Recuero, Fuensanta Gómez-Bernal, Juan Carlos Quevedo-Abeledo, Agustín F. González-Rivero, Elena González-López, J. Gonzalo Ocejo-Vinyals, Alejandro Jimenez-Sosa, Miguel Ángel González-Gay, Iván Ferraz-Amaro
Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) events and CV mortality. Subclinical carotid atherosclerosis is independently associated with rates of incident CV events among patients with RA. The complement system has been related to both the etiopathogenesis of RA and CV disease. In this study, we aimed to evaluate the association between a comprehensive assessment
-
Investigation of ferroptosis-associated molecular subtypes and immunological characteristics in lupus nephritis based on artificial neural network learning Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-07-03 Li Zhang, Qing Yan, Miao Lin, Juanjuan He, Jie Tian, Zhihan Chen, Fuyuan Hong
Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE) with poor treatment outcomes. The role and underlying mechanisms of ferroptosis in LN remain largely unknown. We aimed to explore ferroptosis-related molecular subtypes and assess their prognostic value in LN patients. Molecular subtypes were classified on the basis of differentially expressed ferroptosis-related genes
-
S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-06-25 Hermine I Brunner, Grant S Schulert, Alyssa Sproles, Sherry Thornton, Gabriel Vega Cornejo, Jordi Antón, Ruben Cuttica, Michael Henrickson, Ivan Foeldvari, Daniel J Kingsbury, Margarita Askelson, Jinqi Liu, Sumanta Mukherjee, Robert L Wong, Daniel J Lovell, Alberto Martini, Nicolino Ruperto, Alexei A Grom
Juvenile idiopathic arthritis (JIA) comprises a heterogeneous group of conditions that can cause marked disability and diminished quality of life. Data on predictors of clinical response are insufficient to guide selection of the appropriate biologic agent for individual patients. This study aimed to investigate the propensity of S100A8/9 and S100A12 as predictive biomarkers of abatacept response in
-
The impact of gastroesophageal reflux disease and its treatment on interstitial lung disease outcomes Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-06-25 A. Quinlivan, D. Neuen, D. Hansen, W. Stevens, L. Ross, N. Ferdowsi, S. M. Proudman, J. G. Walker, J. Sahhar, G-S. Ngian, D. Apostolopoulos, L. V. Host, G. Major, C. Basnayake, K. Morrisroe, M. Nikpour
To determine the relationship between gastroesophageal reflux disease (GORD) and its treatment and interstitial lung disease in patients with systemic sclerosis (SSc). SSc patients from the Australian Scleroderma Cohort Study (ASCS) were included. GORD was defined as self-reported GORD symptoms, therapy with a proton pump inhibitor (PPI) or histamine 2 receptor antagonist (H2RA) and/or the presence
-
Impact of RA treatment strategies on lipids and vascular inflammation in rheumatoid arthritis: a secondary analysis of the TARGET randomized active comparator trial Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-06-24 Katherine P. Liao, Pamela Rist, Jon Giles, Leah Santacroce, Margery A. Connelly, Robert J. Glynn, Paul Ridker, Ahmed Tawakol, Joan Bathon, Daniel H. Solomon
Treatments for rheumatoid arthritis (RA) are associated with complex changes in lipids and lipoproteins that may impact cardiovascular (CV) risk. The objective of this study was to examine lipid and lipoprotein changes associated with two common RA treatment strategies, triple therapy or tumor necrosis factor inhibitor (TNFi), and association with CV risk. In this secondary data analysis of the TARGET
-
Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-06-18 Javier Narváez, Elena Cañadillas, Iván Castellví, Juan José Alegre, Vanesa Vincens-Zygmunt, Guadalupe Bermudo, Paola Vidal-Montal, María Molina Molina, Joan Miquel Nolla
To assess the real-world, long-term effectiveness of rituximab (RTX) as a rescue therapy in patients with antisynthetase syndrome and progressive interstitial lung disease (ASS-ILD). Multicentre observational retrospective longitudinal study of a cohort of patients with ASS-ILD that started treatment with RTX due to recurrent or ongoing progressive ILD despite therapy with glucocorticoids and immunosuppressants
-
Baricitinib ameliorates inflammatory and neuropathic pain in collagen antibody-induced arthritis mice by modulating the IL-6/JAK/STAT3 pathway and CSF-1 expression in dorsal root ganglion neurons Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-06-15 Kenta Makabe, Hiroyuki Okada, Naohiro Tachibana, Hisatoshi Ishikura, Norihito Ito, Masaru Tanaka, Ryota Chijimatsu, Asuka Terashima, Fumiko Yano, Meiko Asaka, Dai Yanagihara, Shuji Taketomi, Takumi Matsumoto, Sakae Tanaka, Yasunori Omata, Taku Saito
Janus kinase (JAK) inhibitors, such as baricitinib, are widely used to treat rheumatoid arthritis (RA). Clinical studies show that baricitinib is more effective at reducing pain than other similar drugs. Here, we aimed to elucidate the molecular mechanisms underlying the pain relief conferred by baricitinib, using a mouse model of arthritis. We treated collagen antibody-induced arthritis (CAIA) model
-
Phosphoproteomic profiling of early rheumatoid arthritis synovium reveals active signalling pathways and differentiates inflammatory pathotypes Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-06-12 Cankut Çubuk, Rachel Lau, Pedro Cutillas, Vinothini Rajeeve, Christopher R. John, Anna E. A. Surace, Rebecca Hands, Liliane Fossati-Jimack, Myles J. Lewis, Costantino Pitzalis
Kinases are intracellular signalling mediators and key to sustaining the inflammatory process in rheumatoid arthritis (RA). Oral inhibitors of Janus Kinase family (JAKs) are widely used in RA, while inhibitors of other kinase families e.g. phosphoinositide 3-kinase (PI3K) are under development. Most current biomarker platforms quantify mRNA/protein levels, but give no direct information on whether
-
The integrin CD11b inhibits MSU-induced NLRP3 inflammasome activation in macrophages and protects mice against MSU-induced joint inflammation Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-06-11 Driss Ehirchiou, Ilaria Bernabei, Vishnuprabu Durairaj Pandian, Sonia Nasi, Veronique Chobaz, Mariela Castelblanco, Alexander So, Fabio Martinon, Xiaoyun Li, Hans Acha-Orbea, Thomas Hugle, Li Zhang, Nathalie Busso
In gout, monosodium urate crystals are taken up by macrophages, triggering the activation of the NLRP3 inflammasome and the maturation of IL-1β. This study aimed to investigate the role of integrin CD11b in inflammasome activation in macrophages stimulated by MSU. BMDM from WT and CD11b KO mice were stimulated in vitro with MSU crystals. Cellular supernatants were collected to assess the expression
-
Development of primary osteoarthritis during aging in genetically diverse UM-HET3 mice Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-06-08 Sher Bahadur Poudel, Ryan R. Ruff, Gozde Yildirim, Richard A. Miller, David E. Harrison, Randy Strong, Thorsten Kirsch, Shoshana Yakar
Primary osteoarthritis (OA) occurs without identifiable underlying causes such as previous injuries or specific medical conditions. Age is a major contributing factor to OA, and as one ages, various joint tissues undergo gradual change, including degeneration of the articular cartilage, alterations in subchondral bone (SCB) morphology, and inflammation of the synovium. We investigated the prevalence
-
A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-06-06 Stanley Cohen, Jean S. Beebe, Vishala Chindalore, Shunjie Guan, Mina Hassan-Zahraee, Madhurima Saxena, Li Xi, Craig Hyde, Sarita Koride, Robert Levin, Shannon Lubaczewski, Mikhail Salganik, Abigail Sloan, Erin Stevens, Elena Peeva, Michael S. Vincent, David A. Martin, Myron Chu
The objective of this study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF‑06835375, a potent selective afucosyl immunoglobulin G1 antibody targeting C-X-C chemokine receptor type 5 (CXCR5) that potentially depletes B cells, follicular T helper (Tfh) cells, and circulating Tfh-like (cTfh) cells, in patients with systemic lupus erythematosus (SLE) and rheumatoid
-
Single-cell and genome-wide Mendelian randomization identifies causative genes for gout Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-06-03 Yubiao Yang, Ping Hu, Qinnan Zhang, Boyuan Ma, Jinyu Chen, Bitao Wang, Jun Ma, Derong Liu, Jian Hao, Xianhu Zhou
Gout is a prevalent manifestation of metabolic osteoarthritis induced by elevated blood uric acid levels. The purpose of this study was to investigate the mechanisms of gene expression regulation in gout disease and elucidate its pathogenesis. The study integrated gout genome-wide association study (GWAS) data, single-cell transcriptomics (scRNA-seq), expression quantitative trait loci (eQTL), and
-
Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-06-05 Javier Loricera, Toluwalase Tofade, Diana Prieto-Peña, Susana Romero-Yuste, Eugenio de Miguel, Anne Riveros-Frutos, Iván Ferraz-Amaro, Eztizen Labrador, Olga Maiz, Elena Becerra, Javier Narváez, Eva Galíndez-Agirregoikoa, Ismael González-Fernández, Ana Urruticoechea-Arana, Ángel Ramos-Calvo, Fernando López-Gutiérrez, Santos Castañeda, Sebastian Unizony, Ricardo Blanco
A substantial proportion of patients with giant cell arteritis (GCA) relapse despite standard therapy with glucocorticoids, methotrexate and tocilizumab. The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway is involved in the pathogenesis of GCA and JAK inhibitors (JAKi) could be a therapeutic alternative. We evaluated the effectiveness of JAKi in relapsing
-
Exploration of the combined role of immune checkpoints and immune cells in the diagnosis and treatment of ankylosing spondylitis: a preliminary study immune checkpoints in ankylosing spondylitis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-06-04 Feihong Huang, Zhiping Su, Yibin Huang, Yuxiang Huang, Chengyu Zhou, Sitan Feng, Xiong Qin, Xi Xie, Chong Liu, Chaojie Yu
Immune checkpoints have emerged as promising therapeutic targets for autoimmune diseases. However, the specific roles of immune checkpoints in the pathophysiology of ankylosing spondylitis (AS) remain unclear. Hip ligament samples were obtained from two patient groups: those with AS and femoral head deformity, and those with femoral head necrosis but without AS, undergoing hip arthroplasty. Label-Free
-
Malignancy is increased in patients with antineutrophil cytoplasmic antibody-associated vasculitis in China Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-31 Xiang-Yu Han, Zhi-Ying Li, Ming-Hui Zhao, Mark A. Little, Min Chen
It has been reported that in western countries malignancy risk was higher in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) compared with that in the general population. In the current study, we investigated the incidence, spectrum and risk factors of malignancy in Chinese AAV patients. AAV patients diagnosed from 1995 to 2021 in Peking University First Hospital
-
Predictive models of radiographic progression and pain progression in patients with knee osteoarthritis: data from the FNIH OA biomarkers consortium project Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-30 Xiaoyu Li, Chunpu Li, Peng Zhang
The progression of knee osteoarthritis (OA) can be defined as either radiographic progression or pain progression. This study aimed to construct models to predict radiographic progression and pain progression in patients with knee OA. We retrieved data from the FNIH OA Biomarkers Consortium project, a nested case-control study. A total of 600 subjects with mild to moderate OA (Kellgren-Lawrence grade
-
MiR-653-5p drives osteoarthritis pathogenesis by modulating chondrocyte senescence Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-29 Yucheng Lin, Lu Zhang, Mingliang Ji, Sinuo Shen, Yuzhi Chen, Shichao Wu, Xiaotao Wu, Nancy Q. Liu, Jun Lu
Due to the unclear pathogenesis of osteoarthritis (OA), effective treatment for this ailment is presently unavailable. Accumulating evidence points to chondrocyte senescence as a key driver in OA development. This study aims to identify OA-specific microRNAs (miRNAs) targeting chondrocyte senescence to alleviate OA progression. We screened and identified miRNAs differentially expressed in OA and normal
-
Microstructural changes of the white matter in systemic lupus erythematosus patients without neuropsychiatric symptoms: a multi-shell diffusion imaging study Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-28 Wenjun Hu, Ziru Qiu, Qin Huang, Yuhao Lin, Jiaying Mo, Linhui Wang, Jingyi Wang, Kan Deng, Yanqiu Feng, Xinyuan Zhang, Xiangliang Tan
Diffusion kurtosis imaging (DKI) and neurite orientation dispersion and density imaging (NODDI) provide more comprehensive and informative perspective on microstructural alterations of cerebral white matter (WM) than single-shell diffusion tensor imaging (DTI), especially in the detection of crossing fiber. However, studies on systemic lupus erythematosus patients without neuropsychiatric symptoms
-
The prognosis and management of reclassified systemic lupus erythematosus associated pulmonary arterial hypertension according to 2022 ESC/ERS guidelines Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-27 Yutong Li, Junyan Qian, Xingbei Dong, Jiuliang Zhao, Qian Wang, Yanhong Wang, Xiaofeng Zeng, Zhuang Tian, Mengtao Li
The 2022 European Society of Cardiology/European Respiratory Society (ESC/ERS) guideline has recently revised the hemodynamic definition of pulmonary arterial hypertension. However, there is currently limited research on the prognosis and treatment of system lupus erythematosus-associated pulmonary arterial hypertension (SLE-PAH) patients that have been reclassified by the new hemodynamic definition
-
Epidemiological trends in psoriatic arthritis: a comprehensive population-based study Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-27 Amir Haddad, Perach Chen Elkayam, Nili Stein, Ilan Feldhamer, Arnon Dov Cohen, Walid Saliba, Devy Zisman
Psoriatic arthritis (PsA) is a chronic, potentially debilitating inflammatory arthritis often associated with psoriasis. Understanding the epidemiology of PsA across diverse populations can provide valuable insights into its global burden and the role of genetic and environmental factors. This study aimed to estimate PsA’s temporal trends, prevalence, and incidence, while assessing variations in age
-
Investigating protease-mediated peptides of inflammation and tissue remodeling as biomarkers associated with flares in psoriatic arthritis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-27 Solveig Skovlund Groen, Signe Holm Nielsen, Anne Christine Bay-Jensen, Mozhgan Rasti, Darshini Ganatra, Katerina Oikonomopoulou, Vinod Chandran
Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. PsA disease involves flares, which are associated with increased joint inflammation and tissue remodeling. There is a need for identifying biomarkers related to PsA disease activity and flares to improve the management of PsA patients and decrease flares. The tissue turnover imbalance that occurs during the inflammatory
-
Two-year post-distraction cartilage-related structural improvement is accompanied by increased serum full-length SIRT1 Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-24 Miya Marco, Mylène Jansen, Goran van der Weiden, Eli Reich, Yonathan H. Maatuf, Simon C. Mastbergen, Mona Dvir-Ginzberg
Previously, fragments from Sirtuin 1 (SIRT1) were identified in preclinical and clinical samples to display an increase in serum levels for N-terminal (NT) SIRT1 vs. C-terminal (CT) SIRT1, indicative of early signs of OA. Here we tested NT/CT SIRT1 levels as well as a novel formulated sandwich assay to simultaneously detect both domains of SIRT1 in a manner that may inform us about the levels of full-length
-
Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-24 Victoria Navarro-Compán, Atul Deodhar, Rachid Bahiri, Andrew G. Bushmakin, Joseph C. Cappelleri, Jihane Rammaoui
Tofacitinib is an oral Janus kinase inhibitor for treatment of ankylosing spondylitis (AS). Time to improvement in core domains of AS was estimated in tofacitinib-treated patients with AS. This post hoc analysis used phase 3 trial data from patients with AS receiving tofacitinib 5 mg twice daily or placebo to week (W)16; all patients received open-label tofacitinib W16–48. Outcomes: nocturnal pain;
-
Causal relationship between rheumatoid arthritis and bronchiectasis: a bidirectional mendelian randomization study Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-23 Zehu Chen, Xuegang Li, Honglei Shi, Yiying Huang, Jing Liu
Epidemiological observational studies have elucidated a correlation between rheumatoid arthritis (RA) and bronchiectasis. However, the causal nature of this association remains ambiguous. To clarify this potential causal linkage, we conducted a two-sample Mendelian randomization (MR) analysis to explore the bidirectional causality between RA and bronchiectasis. Summary statistics for RA and bronchiectasis
-
Targeting pathogenic fibroblast-like synoviocyte subsets in rheumatoid arthritis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-23 Hongyan Qian, Chaoqiong Deng, Shiju Chen, Xinwei Zhang, Yan He, Jingying Lan, Aodi Wang, Guixiu Shi, Yuan Liu
Fibroblast-like synoviocytes (FLSs) play a central role in RA pathogenesis and are the main cellular component in the inflamed synovium of patients with rheumatoid arthritis (RA). FLSs are emerging as promising new therapeutic targets in RA. However, fibroblasts perform many essential functions that are required for sustaining tissue homeostasis. Direct targeting of general fibroblast markers on FLSs
-
Dystrophic calcinosis: structural and morphological composition, and evaluation of ethylenediaminetetraacetic acid (‘EDTA’) for potential local treatment Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-22 Phillip Lee, Lorraine Green, Bartosz Marzec, Fiona Meldrum, Francesco Del Galdo, Begonya Alcacer-Pitarch
To perform a detailed morphological analysis of the inorganic portion of two different clinical presentations of calcium-based deposits retrieved from subjects with SSc and identify a chemical dissolution of these deposits suitable for clinical use. Chemical analysis using Fourier Transform IR spectroscopy (‘FTIR’), Raman microscopy, Powder X-Ray Diffraction (‘PXRD’), and Transmission Electron Microscopy
-
The role of M1/M2 macrophage polarization in primary Sjogren’s syndrome Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-14 Xiaochan Chen, Linjiang Zhu, Huaxiang Wu
The purpose of this study was to investigate the role of macrophage polarization in the pathogenesis of primary Sjogren’s syndrome (pSS). Peripheral venous blood samples were collected from 30 patients with pSS and 30 healthy controls. Minor salivary gland samples were abtainted from 10 of these patients and 10 non-pSS controls whose minor salivary gland didn’t fulfill the classification criteria for
-
Identification and verification of a novel signature that combines cuproptosis-related genes with ferroptosis-related genes in osteoarthritis using bioinformatics analysis and experimental validation Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-13 Baoqiang He, Yehui Liao, Minghao Tian, Chao Tang, Qiang Tang, Fei Ma, Wenyang Zhou, Yebo Leng, Dejun Zhong
Exploring the pathogenesis of osteoarthritis (OA) is important for its prevention, diagnosis, and treatment. Therefore, we aimed to construct novel signature genes (c-FRGs) combining cuproptosis-related genes (CRGs) with ferroptosis-related genes (FRGs) to explore the pathogenesis of OA and aid in its treatment. Differentially expressed c-FRGs (c-FDEGs) were obtained using R software. Enrichment analysis